Stem Cells From Human Exfoliated Deciduous Teeth Alleviate Liver Cirrhosis via Inhibition of Gasdermin D-Executed Hepatocyte Pyroptosis

Peng Chen1,2,3†, Yi-kun Zhou1,2,3†, Chun-shan Han1,2,3, Liu-jiang Chen1,2,3, Yi-ming Wang1,2,3, Zi-meng Zhuang1,2,3, Shuai Lin1,2,3, Yan-heng Zhou1,2,3, Jiu-hui Jiang1,2,3* and Rui-li Yang1,2,3*

1 Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China, 2 National Clinical Research Center for Oral Diseases and National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing, China, 3 Beijing Key Laboratory of Digital Stomatology, Beijing, China

Liver cirrhosis represents a type of end-stage liver disease with few effective therapies, which was characterized by damaged functional liver tissue due to long-term inflammation. Gasdermin D (GSDMD)-executed programmed necrosis is reported to be involved in inflammation. However, the role of GSDMD in liver cirrhosis remains unclear. In this study, we used a CCl4-induced cirrhosis model and found stem cells from human exfoliated deciduous teeth (SHED) infusion showed profound therapeutic effects for liver cirrhosis. Mechanistically, NLRP3 inflammasome-activated GSDMD and its pyroptosis were upregulated in liver cirrhosis, while SHED infusion could suppress the expression of GSDMD and Caspase-1, resulting in reduced hepatocyte pyroptosis and inflammatory cytokine IL-1β release. Consistently, SHED could inhibit the elevated expression of NLRP3, GSDMD and Caspase-1 induced by CCl4 treatment in vitro co-culture system, which was mediated by decreasing reactive oxygen species (ROS) generation. Moreover, the pyroptosis inhibitor disulfiram showed similar therapeutic effects for liver cirrhosis as SHED. In conclusion, SHED alleviates CCl4-induced liver cirrhosis via inhibition of hepatocytes pyroptosis. Our findings could provide a potential treatment strategy and novel target for liver cirrhosis.

Keywords: liver cirrhosis, stem cells from human exfoliated deciduous teeth, NLRP3, GSDMD, pyroptosis

INTRODUCTION

Liver cirrhosis is prevalent worldwide and is associated with high morbidity and mortality (1). Cirrhosis is the result of chronic liver inflammation, wherein the normal liver structure is replaced by fibrotic liver nodules and finally leads to liver failure (2). The current drugs and immunotherapy failed to cure patients with liver cirrhosis. Liver transplant is still the most effective cure for liver cirrhosis. However, few patients benefit from organ grafting due to donor organ shortage and the need for lifelong immunosuppressive therapy (3). It is urgent to explore potentially new therapeutic strategies.
Mesenchymal stem cells (MSCs) showed profound immunomodulatory effects except for the capacity for self-renewal and multi-lineage differentiation (4). Recent studies showed that MSCs demonstrated promising therapeutic for several immune diseases, including asthma (5), multiple sclerosis (6), and COVID-19 (7). MSCs are considered to be a feasible cell source, which can be isolated from multiple tissues, such as bone marrow (8), adipose tissue (9), periodontal ligament (10), and dental pulp tissue (11). Among them, stem cells from human exfoliated deciduous teeth (SHED) are relatively new and less studied than MSCs from other sources. SHED is easily obtained and relatively free from ethical concerns compared with MSCs derived from other tissues. SHED exhibited a stronger angiogenesis differentiation, proliferation potential (12), and anti-apoptotic ability over bone marrow MSCs (BMMSCs) (13). SHED was reported to attenuate liver fibrosis by differentiating into hepatocyte-like cells in vivo (14), and SHED-derived hepatocyte transplantation also eliminated liver fibrosis (15). Our previous study showed that SHED could prevent acute hepatitis via inhibition of hepatocyte apoptosis (16). However, the effect of SHED infusion on liver cirrhosis and the underlying mechanism remains elusive.

Pyroptosis is a lytic type of cell death characterized by the activation of inflammatory caspases. Pyroptosis is found to play important roles in a variety of inflammatory diseases, such as sepsis (17), tuberculosis (18), HIV (19), and some neural diseases (20). Gasdermin D (GSDMD) has been identified as the sole effector of pyroptosis. Recently, it is reported that NLR family CARD domain-containing protein 4 (NLRC4) inflammasome was found to mediate the pyroptosis of hepatocytes in non-alcoholic steatohepatitis (NASH) (21). However, whether pyroptosis is involved in liver cirrhosis and the specific effects is still unknown.

In the present study, we evaluated the therapeutic effect of SHED on CCl4-induced mouse liver cirrhosis and revealed that SHED administration attenuated liver cirrhosis by alleviating GSDMD-mediated pyroptosis and inflammation.

MATERIALS AND METHODS

Animals
Female C57BL/6N mice aged 6–8 weeks (body weight 20–21 g) were purchased from Vital River Laboratory (Beijing Vital River Laboratory Animal Technology, Beijing, China). The mice were provided standard chow and water and housed at 22°C–24°C for 1 week before the experiment. The study was authorized by the Peking University Animal Ethics Committee (No. LA2019077).

Liver Cirrhosis Induction
To evaluate the therapeutic effects of SHED, the mice were randomly divided into 3 groups (n = 4): control, CCl4, and CCl4+SHED. A 20% solution of CCl4 in corn oil was injected intraperitoneally into C57BL/6J mice (5 ml/kg) twice a week for 4 weeks (22, 23), and then SHED (1 × 10⁶) suspended in 100 μl of phosphate-buffered saline (PBS) was injected by tail vein injection twice a week (14). The livers were harvested 2 months after induction of liver cirrhosis and treatment.

To evaluate the therapeutic effects of disulfiram, the mice were randomly divided into 3 groups (n = 4): control, CCl4, and CCl4+disulfiram (a Food and Drug Administration (FDA)-approved pyroptosis inhibitor). A 20% solution of CCl4 in corn oil was injected intraperitoneally into C57BL/6J mice (5 ml/kg) twice a week for 4 weeks (22), and then disulfiram dissolved in corn oil was injected intraperitoneally (10 mg/kg) once a week. The livers were harvested 2 months after induction of liver cirrhosis and treatment.

Biochemical Indicator Analysis of Mouse Serum Blood Samples
The serum was separated to detect the biochemical indexes. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured by Elisa kit (Changchun Huili Biotech, Changchun, China) according to the manufacturer’s instructions. They are commonly clinically measured as markers for liver dysfunctions. For the ALT and AST assays, 10 μl of serum was used.

Optical Imaging
Mice were intravenously injected with prepared DiR-labeled SHED in PBS and scanned at 1 and 3 days post-injection using an Interactive Video Information System Lumina Series III in vivo Imaging System (Caliper Life Sciences, PerkinElmer, Waltham, MA, USA). Ex vivo imaging was carried out immediately afterward by imaging excised major organs (heart, lung, liver, spleen, and kidney).

Frozen Sections
SHED was labeled with 5-(and-6)-carboxy fluorescein diacetate succinimidyl ester (CFSE; Molecular Probes Biotec Co., Eugene, OR, USA) and diluted to 1 × 10⁷/ml for transplantation. The livers were flash-frozen at an optimum cutting temperature at 1 and 3 days post-injection. Nuclear staining was performed with diamidine phenyl indole (DAPI) mounting medium (Vector Lab, Burlingame, CA, USA). The positions of CFSE-labeled SHED cells could be traced using a confocal laser scanning microscope (Zeiss, Thornwood, NY, USA).

H&E Staining
The livers were harvested and then fixed in 4% paraformaldehyde for 24 h at 4°C. Having been paraffin-embedded and sectioned into 5-μm pieces, deparaffinization and rehydration of sections were done. Then sections were stained with H&E staining kits (Solarbio, Beijing, China) in accordance with the manufacturer’s instructions. Images were captured by an inverted microscope.

Masson Trichrome Staining
The liver tissue sections were stained with modified Masson trichrome staining kits (Solarbio, China) in accordance with the manufacturer’s instructions. The level of liver fibrosis was evaluated by calculating the percentage of the blue region (collagen) by ImageJ software. Three fields of view were
randomly selected from each specimen (n = 3) for semiquantitative analysis of the collagen/matrix content.

**Sirius Red Staining**

Sirius red staining was carried out according to the instructions of the Sirius red staining kits (Novo Scientific, Beijing, China). The sections were stained with Sirius red for 1 h. For collagen deposition determination, three randomly selected fields from each slice were visualized and quantified using ImageJ software.

**Immunohistochemistry**

The enzymatic antigen retrieval method was used with trypsin and proteinase K at a ratio of 1,000:1. Endogenous peroxidase blocking was done using hydrogen peroxide, while 5% bovine serum albumin (BSA) was used to reduce non-specific protein reactions. Primary antibodies GSDMD (1:600) (Abcam, Cambridge, UK; ab219800), Caspase-1 (1:600) (ProteinTech, Chicago, IL, USA; 22915-1-AP), and NLRP3 (1:300) (Thermo Fisher, Waltham, MA, USA; PA5-79740) were dissolved in blocking buffer (Zhongshan Golden Bridge, Beijing, China). The diluted primary antibody was added to each slide and incubated overnight at 4°C. After being washed three times with PBS to remove the redundant primary antibodies, the slides were incubated with secondary goat anti-rabbit lgG (Zhongshan Golden Bridge, China) at 37°C for 60 min. The color intensification was done with a DAB chromogen kit (Zhongshan Golden Bridge, China) and followed by hematoxylin staining. Three fields of view were randomly selected from each specimen (n = 3) for semiquantitative analysis, and the positive-staining cells were counted by ImageJ software.

**Cell Culture**

Mouse hepatic cell line NCTC1469 was purchased from Saibai Biotechnology. NCTC cells were cultured in high-glucose Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin at 37°C with 5% CO2. For the CCl4 treatment group, the SHED and NCTC were seeded in the upper chamber. These plates were then incubated at 37°C for 8 h for further investigation.

**Intracellular Reactive Oxygen Species Analysis**

Reactive oxygen species (ROS) detection kits were purchased from Solarbio Company (Beijing, China). The cultured NCTC were collected as single-cell suspension and then incubated with 2,7'-dichlorofluorescin diacetate (DCFH-DA) in the dark at 37°C for 30 min. The DCFH-DA fluorescent probe oxidized by ROS was analyzed using a flow cytometer (BD Accuri C6, BD Biosciences, San Jose, CA, USA).

**Propidium Iodide Staining**

Propidium iodide staining was performed using a propidium iodide (PI) staining kit (Nanjing kaiji Bio-Tek Corporation, Nanjing, China). The cells were incubated with a PI solution for 30 min, followed by counterstaining with DAPI. Then, images were taken under a fluorescence microscope. The cell death rate was counted by the ratio of red/blue fluorescence intensity using ImageJ software. Three visual fields were selected for each group and photographed under a fluorescence microscope.

**Determination of Mitochondrial Membrane Potential**

Mitochondrial membrane potential (MMP) was determined by using MMP assay kits with JC-1 (Solarbio, China). JC-1 working solution measuring 1 µg/ml was prepared and incubated with cells at 37°C for 20 min. The level of MMP depolarization was identified by the red/green fluorescence intensity ratio. Three visual fields were selected for each group and photographed under a fluorescence microscope.

**Immunofluorescence Staining**

NCTC cells were seeded on chamber slides and fixed with 4% paraformaldehyde. The chamber slides were incubated with primary antibodies GSDMD (Abcam, ab219800), Caspase-1 (1:200) (ProteinTech, 22915-1-AP), and NLRP3 (1:200) (Thermo Fisher, PA5-79740) at 4°C overnight and then treated with sheep anti-rabbit conjugated with fluorescein isothiocyanate (FITC) (1:200) for 1 h at room temperature. Finally, the slides were mounted with a mounting medium containing DAPI. Three visual fields were selected for each group and photographed under a fluorescence microscope. Image analysis was performed using ImageJ.

**Quantitative Real-Time PCR Assay**

RNA was extracted from NCTC cells with TRIzol reagent (Sigma, USA), and 2 µg of RNA was reverse transcribed into complementary first-strand cDNA using cDNA synthesis kits (Takara Bio, Inc., Otsu, Japan). Real-time PCR quantification was performed using the SYBR Green Mix (Applied Biosystems, Foster City, CA, USA). Target gene expressions were calculated by their ratios to β-actin. The sequences of primers were as follows: Caspase-1 forward: 5′-GATCAACACTCGGCTCA CGTC-3′, Caspase-1 reverse: 5′-AGCTCCAACCCCTC GAGAAA-3′; GSDMD forward: 5′-TTCA GCCCTAC TGCCCTTCT-3′, GSDMD reverse: 5′-GGTGA CACATGAA.
TAACGGGGTT-3'; IL-1β forward: 5'-TTCAGGCAGGCA GTATCACCT-3'; IL-1β reverse: 5'-GAAGGTCCACGGGA AAGACAC-3'.

**Western Blotting Analysis**

Total protein was lysed in radioimmunoprecipitation assay (RIPA) buffer (Highly Efficient Solitaire, Solarbio, China) containing 100 μM of phenylmethylsulfonyl fluoride (PMSF) (Solarbio, China) and protease inhibitor cocktail (Abcam, Waltham, MA, USA). Proteins measuring 25 μg were loaded and separated into 4%–12% NuPAGE gel (Beyotime, Shanghai, China), and they were transferred to 0.2 μm of nitrocellulose membranes (Millipore, Billerica, MA, USA). Then 0.1% Tween-20 and 5% BSA were provided to block the membranes for 1 h, followed by overnight incubation with primary antibodies (1:1,000). The membranes were washed and incubated for 1 h in horseradish peroxidase (HRP)-conjugated secondary antibody at 1:5,000 (Zhongshan Golden Bridge, China). Super Signal West Pico Chemiluminescent Substrate (Thermo) and BioMax film (Kodak, Rochester, New York, USA) were used to detect the immunoreactive proteins.

**Statistics Analysis**

Statistical analysis was performed with GraphPad Prism 9.0 software. Comparisons between two groups were analyzed using independent unpaired two-tailed Student's t-tests, and comparisons among more than two groups were analyzed using a one-way ANOVA with the Bonferroni correction if the data did not meet the normality distribution assumption. p-Values <0.05 were considered statistically significant.

**RESULTS**

**Stem Cells From Human Exfoliated Deciduous Teeth Administration Attenuated CCl4-Induced Liver Cirrhosis**

Mouse liver cirrhosis was induced by intraperitoneal injection of CCl4 for 4 weeks, and SHED (1 × 10⁶) cells were injected via tail vein to analyze their therapeutic effects (Figure 1A). Liver function was determined by ALT and AST levels, and the results showed that the level of ALT and AST was higher in the CCl4 group compared with the control one, and SHED administration significantly decreased the level of ALT and AST levels as compared with the CCl4 group (Figures 1B, C). The CCl4 group showed more fibrosis and effusion compared with the control group, while SHED infusion could significantly improve the morphology of the liver (Figure 1D). There were more swelling cells, inflammatory cells infiltration, and disorganized liver cells arrangement in the CCl4 group compared with the control group, and SHED treatment significantly ameliorated the swelling cells and the tissue inflammation, as assessed by H&E staining (Figure 1E). Moreover, Masson trichrome staining showed that collagen deposition was significantly increased in the CCl4 group, while SHED infusion could decrease the collagen deposition (Figures 1F, G). Sirius red staining showed that collagen fibers expanded outward from the portal area and formed fibrous septum in the CCl4 group, while SHED infusion reduced the formation of the fibrous septum (Figures 1H, I). These results indicated that SHED administration could reduce the CCl4-induced mouse liver injury.

**Stem Cells From Human Exfoliated Deciduous Teeth Infusion Inhibited Pyroptosis of Hepatocytes in CCl4-Induced Liver Cirrhosis**

Pyroptosis plays important roles in inflammation (24). It is reported that hepatocyte pyroptosis may be involved in NASH (25, 26). The expression of GSDMD, a key pyroptosis executioner, was significantly increased in the CCl4-treated group compared with the control ones. With the treatment of SHED, the ratio of GSDMD positive cells was significantly decreased (Figure 2A, B). Then we analyzed the expression of Caspase-1 and NLRP3, the upstream molecules of GSDMD, and inflammatory cytokines IL-1β in liver tissue. Results showed that the expression of Caspase-1, NLRP3, and IL-1β was significantly upregulated in the CCl4 group. With the infusion of SHED, the expression of Caspase-1, NLRP3, and IL-1β was decreased (Figures 2C–H). NLRP3–Caspase-1–GSDMD is known as a classical pathway of pyroptosis (27). After NLRP3 activation, pro-IL-1β is cleaved into mature and active IL-1β mediated by Caspase-1, and active IL-1β is secreted extracellularly by the GSDMD pore to exert an inflammatory effect (28). These results indicated that SHED infusion attenuated liver cirrhosis through inhibited pyroptosis.

**Stem Cells From Human Exfoliated Deciduous Teeth Inhibited NLRP3 Inflammasome Activation and Pyroptosis in Hepatocytes**

The expression of GSDMD and Caspase-1 in mouse hepatic cell line NCTC 1469 was significantly upregulated after being stimulated with CCl4 for 3 h, as assessed by qPCR (Figures 3A, B). The expression of inflammatory cytokine IL-1β was also increased after CCl4 treatment (Figure 3C). The expression of NLRP3, Caspase-1, and GSDMD-C was significantly elevated after CCl4 stimulation, which was inhibited when co-cultured with SHED in the transwell system (Figures 3D–H). Immunofluorescence results showed that CCl4 activated the expression of NLRP3, Caspase-1, and GSDMD to increase in hepatocytes, while SHED treatment with a transwell system significantly downregulated their expression (Figures 3I–K). Compared with the control group, the CCl4 group showed more dead cells positive for PI staining, while SHED treatment reduced the number of PI-positive dead hepatocytes in the lower chamber, which indicated that SHED suppressed the pyroptosis of hepatocytes (Figure 3L).

**Stem Cells From Human Exfoliated Deciduous Teeth Inhibited Reactive Oxygen Species**

ROS is considered to play a role in pyroptosis (29). The production of ROS in hepatocytes was increased after CCl4
treatment, as assessed by flow cytometry analysis (Figures 4A, B). A decrease in MMP after CCl4 stimulation was detected by the ratio of green and red fluorescence, as assessed by the JC-1 MMP detection kit (Figures 4C, D). After being treated with SHED in transwell, ROS production was downregulated, and MMP was restored (Figures 4A–D). To analyze the effects of ROS on hepatocyte pyroptosis, antioxidant [N-acetylcysteine (NAC)], a ROS inhibitor, was used to treat hepatocytes. The results showed that the elevated expression of NLRP3, Caspase-1, and GSDMD-C induced by CCl4 treatment was suppressed by NAC treatment (Figures 4E–I). These data showed that SHED attenuated CCl4-induced pyroptosis of hepatocytes by reducing ROS.

**Pyroptosis Inhibitor Disulfiram Attenuated CCl4-Induced Liver Cirrhosis**

To verify the effects of pyroptosis on liver cirrhosis, we used disulfiram, a potent inhibitor of GSDMD (30), to treat liver cirrhosis (Figure 5A). The results showed that the levels of ALT and AST in mouse serum were decreased after disulfiram administration compared with the CCl4 group (Figures 5B, C). The liver fibrosis was decreased, and the gross morphology of the
liver was improved after disulfiram treatment compared with the CCl₄ group (Figure 5D). The disorganized liver cells arrangement, swelling cells, and inflammation in liver tissue were decreased in the disulfiram treatment group, as assessed by H&E staining (Figure 5E). The collagen deposition was also decreased in Masson trichrome staining in the disulfiram group when compared with the CCl₄ group (Figures 5F, G). Compared with the CCl₄ group, there were fewer fibrous septa formed in the disulfiram treatment group (Figures 5H, I). With the treatment of disulfiram, the expression of IL-1β was decreased after disulfiram treatment compared with the CCl₄ group (Figures 5J, K). These results implied an important role of pyroptosis in the pathogenesis of liver cirrhosis and suggested a potential therapeutic strategy of targeting GSDMD-mediated pyroptosis in liver cirrhosis treatment (Figure 6).

**DISCUSSION**

In this study, we showed that SHED could attenuate liver cirrhosis. The important finding from this study is that...
GSDMD-induced pyroptosis was involved in murine liver cirrhosis. Moreover, SHED could suppress pyroptosis and protect liver cells from injury. The expression of GSDMD and Caspase-1 was increased in the liver cirrhosis group. The inhibitor of GSDMD, disulfiram, showed therapeutic effects for liver cirrhosis similar to SHED infusion. These data suggest that GSDMD plays an important role in the process of liver cirrhosis and may be a potential target for new therapeutic strategy exploration.

GSDMD is recently reported to execute programmed necrosis in inflammation, and GSDMD-formed pores allow inflammatory cytokine IL-1β release. IL-1β has been well studied to be an important pro-inflammatory cytokine that drives the pathogenesis of liver inflammation, fibrosis, and injury (31). In this study, we found that the IL-1β release was increased after CCl4 treatment. The maturation of pro-inflammatory cytokines such as pro-IL-1β and pro-IL-18 was mediated by the activation of Caspase-1. NLRP3 binds to pro-Caspase-1 and subsequently

FIGURE 3 | SHED inhibited CCl4-induced NLRP3 inflammasome activation and pyroptosis in hepatocytes. (A–C) The mRNA level of Caspase-1, GSDMD, and IL-1β was detected after 3h and 6h CCl4 stimulation analyzed by RT-qPCR. (D–H) The expression levels of NLRP3, Caspase-1, and GSDMD-C in hepatocytes in control, CCl4, and SHED infusion group by Western blotting analysis. (I–K) The expression of NLRP3, Caspase-1 and GSDMD in hepatocytes in control, CCl4, and CCl4+SHED groups was analyzed by immunofluorescence staining. (L) The ratio of dead cells was determined by PI staining in control, CCl4, and CCl4+SHED groups. Scale bar: 50 μm. *p < 0.05, **p < 0.01, and ***p < 0.001. Graph bars show the mean ± SD. All of the assays were performed in triplicate. PI, propidium iodide; SHED, stem cells from human exfoliated deciduous teeth; GSDMD, gasdermin D.
activates Caspase-1 (32). GSDMD is found to be a downstream molecule of Caspase-1 and cut into cleaved N-terminal GSDMD (GSDMD-N) and cleaved C-terminal GSDMD (GSDMD-C). GSDMD-N is identified to be the effective form to trigger pyroptosis by punching pores in the cell membrane, and it is inhibited by GSDMD-C when they are combined together (33). GSDMD-C also mediates the identification process of caspases and GSDMD, and the Caspase–GSDMD-C complex promotes dimerization-mediated caspase activation, rendering a cleavage independently of the cleavage-site tetrapeptide sequence (34).

Matured IL-1β and IL-18 leak from the pores and amplify the inflammatory response. Here we showed that hepatocyte undergoing pyroptosis was mediated by NLRP3 in liver cirrhosis. It is reported that NLRC4 inflammasome was found to mediate the pyroptosis of hepatocytes in NASH, while NLRP3 knockout mice were not protected against hepatocyte pyroptosis (21). Caspase-11-mediated pyroptosis of hepatocytes was also reported to be involved in alcoholic hepatitis (35). Whether NLRC4 or Caspase-11 participates in liver cirrhosis needs further investigation.

GSDMD is a member of a family of conserved proteins that include gadermin A, B, C, D, and E and DFNB59 (33), and most of them have now been shown to have pore-forming activity. GSDMA is expressed in epithelial cells and has been linked to autoimmune diseases and cancer (36). GSDMB is reported to be associated with asthma and colitis (37). GSDME is reported to promote inflammation and fibrosis in obstructive nephropathy (38). Recent studies demonstrate that the function of the gasdermin family still remains explored, and there are pathways of pyroptosis waiting to be discovered (39–41). The exact role of the GSDM family members and pathways of pyroptosis in liver cirrhosis still needs further exploration.

Disulffiram has been used as a treatment for alcoholism and proved relatively safe and is well tolerated by most patients (42). Recently, it was found to block pyroptosis and cytokine release in cells by inhibiting GSDMD pore formation, while it did not substantially inhibit inflammasome activation and GSDMD processing in cells (32). In our experiment, we found that disulffiram could improve liver dysfunction similar to SHED.
infusion, which verified the role of pyroptosis in liver fibrosis and implied the potential therapeutic targets.

Abnormal mitochondrial functions are linked to multiple diseases including liver fibrosis (43). Acute damage can trigger the permeabilization of mitochondrial membranes to initiate apoptosis or necrosis (44). Mitochondria house their own genome organized into DNA-protein complexes, the mitochondrial nucleoids. Exposed to the ROS, mitochondrial...
DNA (mtDNA) is at risk for oxidative damage and leaks into the cytosol, which may trigger inflammasome pyroptotic cell death (45) (46). We found that the cellular ROS was increased and the MMP was decreased in CCl4-induced hepatocytes, which indicated that CCl4 stimulation caused the dysfunction of mitochondria. NLRP3 inflammasome is reported to sense mitochondrial dysfunction (47), and it might cause the activation of the downstream pyroptosis pathway in hepatocytes. When treated with SHED, the ROS generation was suppressed and MMP returned to a relatively normal level. When treated with NAC, a ROS inhibitor, the pyroptosis pathway was also inhibited. We showed that SHED could decrease the ROS generation and restore the mitochondria function to protect hepatocytes from pyroptosis.

In this study, SHED infusion displayed an anti-pyroptosis effect in transwell co-culture experiments, indicating that this effect may be mediated by paracrine secretory factors. It has been reported that MSCs can secrete lots of molecules, such as soluble proteins, lipids, and extracellular vesicles (EVs). MSC-sourced secretome shows profound immunomodulatory and anti-inflammatory effects in a variety of diseases. Anti-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and IL-10 are reported to inhibit the proliferation of hepatic stellate cells and decrease collagen synthesis (48, 49). Hepatocyte growth factor-1 (HGF-1) and vascular endothelial growth factor (VEGF) secreted by MSCs can stabilize the barrier function of endothelial cells (50), which may reduce the damage to liver tissue. Recent studies have shown that exosomes are one of the key secretory products of MSCs mediating cell-to-cell communication. Exosome cargo consists of proteins, microRNA (miRNA), mRNA, and mitochondria (51). MSC-derived exosomes containing miR-542-3p are reported to reduce the expression of ROS and induce cell inflammatory response via inhibiting TLR4 (52), and the mitochondrial transfer was also reported to play a role in the therapeutic restoration of mitochondrial function by MSC-derived exosomes (53). The exact molecules that displayed the anti-pyroptosis effect in SHED need further investigation. Early studies indicated that SHED may promote liver tissue repair via differentiating into hepatocyte-like cells (14). By tracing SHED with DiR and CFSE labels, our study showed that SHED was recruited in the liver 1 day after transplantation and decreased in a time-dependent manner (16). It is reported that the apoptosis of the infusion MSCs increased in a time-dependent manner and display its immunosuppressive by recruiting T cells for FasL-mediated apoptosis or inducing indoleamine 2,3-dioxygenase (IDO) production in recipient phagocytes (54, 55). Autophagy of MSCs was also reported to be induced by a liver fibrosis environment (56). These results indicated that the therapeutic effects of SHED for liver cirrhosis may be dependent on the synergism of paracrine molecules and differentiating into hepatocyte-like cells. However, the precise mechanism for MSC infusion to treat liver cirrhosis needs further investigation.

**CONCLUSION**

In summary, the present study demonstrated that SHED infusion attenuated liver damage by inhibiting the GSDMD-executed pyroptosis pathway in CCl4-induced liver cirrhosis. SHED treatment inhibited inflammasome NLRP3 activation by reducing ROS generation. Moreover, the pyroptosis inhibitor disulfram also showed therapeutic effects for liver cirrhosis. SHED infusion and the targets on GSDMD may be potential novel therapeutic strategies for liver cirrhosis.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Ethics Committee of Peking University.

**AUTHOR CONTRIBUTIONS**

PC and Y-kZ contributed to the collection and assembly of data, data analysis and interpretation, and manuscript drafting. C-sH, Y-mW, Z-mZ, SL, and L-jC contributed to the animal study. R-lY and J-hJ contributed to the overall design of the study, critical editing of the manuscript, and financial support. All authors read and approved the final manuscript.

**FUNDING**

This work was supported by the National Natural Science Foundation of China No. 81970940 (R-lY), Ten-thousand Talents Program QNBJ-2020 (R-lY), and the National Science and Technology Major Project of the Ministry of Science and Technology of China No. 2018ZX10302207.
REFERENCES

1. Sepanlou SG, Safiri S, Bisignano C, Itaka KS, Merat S, Saberifiroozoi M, et al. The Global, Regional, and National Burden of Cirrhosis in Cause in 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol (2020) 5:245–66. doi: 10.1016/S2468-1593(19)30439-9

2. Pellicer A, Ramachandran P, Iredale JP, Fallowfield JA. Liver Fibrosis and Repair: Immune Regulation of Wound Healing in a Solid Organ. Nat Rev Immunol (2014) 14:181–94. doi: 10.1038/nri3623

3. Petersen BE, Bowen WC, Patrène KD, Mars WM, Sullivan AK, Murase N, et al. Bone Marrow as a Potential Source of Hepatic Oval Cells. Science (1999) 284:1168–70. doi: 10.1126/science.284.5417.1168

4. Fong S-B, Zhang H-Y, Wang C, He B-X, Liu X-Q, Meng X-C, et al. Small Extracellular Vesicles Derived From Human Mesenchymal Stromal Cells Prevent Group 2 Innate Lymphoid Cell-Dependent Allergic Airway Inflammation Through Delivery of miR-146a-Sp1. J Extracell Vesicles (2020) 9:1723260. doi: 10.1080/20130187.2020.1723260

5. Petrou P, Kassis I, Levin N, Paul F, Backner Y, Benoliel T, et al. Beneficial Effects of Autologous Mesenchymal Stem Cell Transplantation in Active Progressive Multiple Sclerosis. Brain (2020) 143:3574–88. doi: 10.1093/brain/awaa333

6. Zhu R, Yan T, Feng Y, Liu Y, Cao H, Peng G, et al. Mesenchymal Stem Cell Regulation of CCl4-Induced Liver Cirrhosis by Hepatically Differentiated Human Exfoliated Deciduous Teeth in Liver Fibrosis in Mice. J Exp Med (2019) 216:2562–81. doi: 10.1084/jem.20190377

7. Wang D, Zheng J, Hu Q, Zhao C, Chen Q, Shi P, et al. Magnesium Protects Against Septis by Blocking Gasdermin D-N-Terminal-Induced Pyroptosis. Cell Death Differ (2020) 27:466–81. doi: 10.1038/s41418-019-0366-x

8. Beckwith KS, Beckwith MS, Ullmann S, Saettia RS, Kim H, Marstad A, et al. Plasma Membrane Damage Causes NLPR3 Activation and Pyroptosis During Mycobacterium Tuberculosis Infection. Nat Commun (2020) 11:2270. doi: 10.1038/s41467-020-16143-6

9. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell Death by Pyroptosis Drives CD4+ T-Cell Depletion in HIV-1 Infection. Nature (2014) 505:509–14. doi: 10.1038/nature12940

10. Li S, Wu Y, Yang D, Wu C, Ma C, Liu X, et al. Gasdermin D In Peripheral Myeloid Cells Drives Neuroinflammation in Experimental Autoimmune Encephalomyelitis. J Exp Med (2019) 216:2562–81. doi: 10.1084/jem.20190377

11. Xie J, Zhao YM, Rao NQ, Wang XT, Fang TJ, Li XX, et al. Comparative Study of Postnatal Human Dental Pulp Stem Cells. Cell Research (2015) 6:171. doi: 10.1186/s41422-016-00573-y

12. Xie J, Zhao YM, Rao NQ, Wang XT, Fang TJ, Li XX, et al. Comparative Study of Postnatal Human Dental Pulp Stem Cells. Cell Research (2015) 6:171. doi: 10.1186/s41422-016-00573-y

13. Chen C, Liu J, Guo H, Yang Y, Zhang X, et al. SHED Alleviates Liver Cirrhosis. Frontiers in Immunology | www.frontiersin.org May 2022 Volume 13 Article 860225

14. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal Human Dental Pulp Stromal Cells Prevent Group 2 Innate Lymphoid Cell-Dependent Allergic Airway Inflammation Through Delivery of miR-146a-Sp1. J Extracell Vesicles (2020) 9:1723260. doi: 10.1080/20130187.2020.1723260

15. Hayatka A, Koch J, Schuppen D, Maddrey WC, Hahn EG. The Serum Concentrations of the Aminoterminal Propeptide of Procollagen Type-III and the Hepatic Content of Messenger-Rna for the Alpha-1 Chain of Procollagen Type-Ii in Carbon Tetrachloride-Induced Rat-Liver Fibrogenesis. J Hepatol (1991) 13:328–38. doi: 10.1016/0168-8278(91)90077-O

16. Bergsakken T, Fink SL, Cookson BT. Pyroptosis: Host Cell Death and Inflammation. Nat Rev Microbiol (2009) 7:99–109. doi: 10.1038/nrmicro2070

17. Hirsova P, Gores GJ. Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis. Cell Mol Gastroenterol Hepatol (2013) 1:17–27. doi: 10.1016/j.cmh.2012.11.005

18. Xue B, Jiang M, Chu Y, Wang W, Chen D, Li X, et al. Gasdermin D Plays a Key Role as a Pyroptosis Executor of Non-Alcoholic Steatohepatitis in Humans and Mice. J Hepatol (2018) 68:773–82. doi: 10.1016/j.jhep.2017.11.040

19. Wang D, Zheng J, Hu Q, Zhao C, Chen Q, Shi P, et al. Magnesium Protects Against Septis by Blocking Gasdermin D-N-Terminal-Induced Pyroptosis. Cell Death Differ (2020) 27:466–81. doi: 10.1038/s41418-019-0366-x

20. Beckwith KS, Beckwith MS, Ullmann S, Saettia RS, Kim H, Marstad A, et al. Plasma Membrane Damage Causes NLPR3 Activation and Pyroptosis During Mycobacterium Tuberculosis Infection. Nat Commun (2020) 11:2270. doi: 10.1038/s41467-020-16143-6

21. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell Death by Pyroptosis Drives CD4+ T-Cell Depletion in HIV-1 Infection. Nature (2014) 505:509–14. doi: 10.1038/nature12940

22. Li S, Wu Y, Yang D, Wu C, Ma C, Liu X, et al. Gasdermin D In Peripheral Myeloid Cells Drives Neuroinflammation in Experimental Autoimmune Encephalomyelitis. J Exp Med (2019) 216:2562–81. doi: 10.1084/jem.20190377

23. Koh EH, Yoon JE, Ko MS, Leem J, Yun J-Y, Hong CH, et al. Spingomelin Synthase 1 Mediates Hepatocyte Pyroptosis to Trigger Non-Alcoholic Steatohepatitis. Gut (2021) 70:1954–64. doi: 10.1136/gutjnl-2020-322509

24. Sakaide I, Terai S, Yamamoto N, Aoyama T, Ishikawa T, Nishina H, et al. Transplantation of Bone Marrow Cells Reduces CCl4-Induced Liver Fibrosis in Mice. Hepatology (2004) 40:1304–11. doi: 10.1002/hep.20452

25. Hayatka A, Koch J, Schuppen D, Maddrey WC, Hahn EG. The Serum Concentrations of the Aminoterminal Propeptide of Procollagen Type-III and the Hepatic Content of Messenger-Rna for the Alpha-1 Chain of Procollagen Type-Ii in Carbon Tetrachloride-Induced Rat-Liver Fibrogenesis. J Hepatol (1991) 13:328–38. doi: 10.1016/0168-8278(91)90077-O

26. Bergsakken T, Fink SL, Cookson BT. Pyroptosis: Host Cell Death and Inflammation. Nat Rev Microbiol (2009) 7:99–109. doi: 10.1038/nrmicro2070

27. Hirsova P, Gores GJ. Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis. Cell Mol Gastroenterol Hepatol (2013) 1:17–27. doi: 10.1016/j.cmh.2012.11.005

28. Xue B, Jiang M, Chu Y, Wang W, Chen D, Li X, et al. Gasdermin D Plays a Key Role as a Pyroptosis Executor of Non-Alcoholic Steatohepatitis in Humans and Mice. J Hepatol (2018) 68:773–82. doi: 10.1016/j.jhep.2017.11.040

29. Hayatka A, Koch J, Schuppen D, Maddrey WC, Hahn EG. The Serum Concentrations of the Aminoterminal Propeptide of Procollagen Type-III and the Hepatic Content of Messenger-Rna for the Alpha-1 Chain of Procollagen Type-Ii in Carbon Tetrachloride-Induced Rat-Liver Fibrogenesis. J Hepatol (1991) 13:328–38. doi: 10.1016/0168-8278(91)90077-O
Sclerosis and Mediate GSDMA Contribution to Disease Risk. *Ann Rheum Dis* (2018) 77:596–601. doi: 10.1136/annrheumdis-2017-212454

41. Xi R, Montague J, Lin X, Lu C, Lei W, Tanaka K, et al. Up-Regulation of Gasermin C in Mouse Small Intestine Is Associated With Lytic Cell Death in Enterocytes in Worm-Induced Type 2 Immunity. *Proc Natl Acad Sci USA* (2021) 118:e2026307118. doi: 10.1073/pnas.2026307118

42. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram Treatment of Alcoholism. A Veterans Administration Cooperative Study. *JAMA* (1986) 256:1449–55. doi: 10.1001/jama.256.11.1449

43. An P, Wei L-L, Zhao S, Sverdlov DY, Vaid KA, Miyamoto M, et al. Hepatocyte Mitochondria-Derived Danger Signals Directly Activate Hepatic Stellate Cells and Drive Progression of Liver Fibrosis. *Nat Commun* (2020) 11:2362. doi: 10.1038/s41467-020-16902-0

44. Kroemer G, Galluzzi L, Brenner C. Mitochondrial Membrane Permeabilization in Cell Death. *Physiol Rev* (2007) 87:99–163. doi: 10.1152/physrev.00013.2006

45. Evavold CL, Hafner-Bratkovic I, Devant P, D’Andrea JM, Ngwa EM, Borsic E, et al. Control of Gasermin D Oligomerization and Pyroptosis by the Regulator-Rag-Mtorc1 Pathway. *Cell* (2021) 184:4495–511.e19. doi: 10.1016/j.cell.2021.06.028

46. Li Y, Shen Y, Jin K, Wen Z, Cao W, Wu B, et al. The DNA Repair Nuclease MRE11A Functions as a Mitochondrial Protector and Prevents T Cell Pyroptosis and Tissue Inflammation. *Cell Metab* (2019) 30:477–92.e6. doi: 10.1016/j.cmet.2019.06.016

47. Zhou R, Yadi AS, Menu P, Tschopp J. A Role for Mitochondria in NLRP3 Inflammasome Activation. *Nature* (2011) 469:221–5. doi: 10.1038/nature09663

48. Choi JS, Jeong IS, Han JH, Cheon SH, Kim S-W. IL-10-Secreting Human MSCs Generated by TALEN Gene Editing Ameliorate Liver Fibrosis Through Enhanced Anti-Fibrotic Activity. *Biomater Sci* (2019) 7:1078–87. doi: 10.1039/c8bm01347k

49. Parekkadan B, van Poll D, Megeed Z, Kobayashi N, Tilles AW, Berthiaume F, et al. Immunomodulation of Activated Hepatic Stellate Cells by Mesenchymal Stem Cells. *Biochem Biophys Res Commun* (2007) 363:247–52. doi: 10.1016/j.bbrc.2007.05.150

50. Yang Y, Chen Q-H, Liu A-R, Xu X-P, Han J-B, Qiu H-B. Synergism of MSC-Secreted HGF and VEGF in Stabilising Endothelial Barrier Function Upon Lipopolysaccharide Stimulation via the Rac1 Pathway. *Stem Cell Res Ther* (2015) 6:250. doi: 10.1186/s13287-015-0257-0

51. Hough KP, Trevor JL, Strenkowski JG, Wang Y, Chacko BK, Tousif S, et al. Exosomal Transfer of Mitochondria From Airway Myeloid-Derived Regulatory Cells to T Cells. *Redox Biol* (2018) 18:54–64. doi: 10.1016/j.redox.2018.06.009

52. Cai G, Cai G, Zhou H, Zhuang Z, Liu K, Pei S, et al. Mesenchymal Stem Cell-Derived Exosome miR-542-3p Suppresses Inflammation and Prevents Cerebral Infarction. *Stem Cell Res Ther* (2021) 12:2. doi: 10.1186/s13287-020-02030-w

53. Li X, Michaeloudes C, Zhang Y, Wiegman CH, Adcock IM, Lian Q, et al. Mesenchymal Stem Cells Alleviate Oxidative Stress-Induced Mitochondrial Dysfunction in the Airways. *J Allergy Clin Immunol* (2018) 141:1634–45.e5. doi: 10.1016/j.jaci.2017.08.017

54. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, et al. Mesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell Apoptosis. *Cell Stem Cell* (2012) 10:544–55. doi: 10.1016/j.stem.2012.03.007

55. Galleu A, Rifo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, et al. Apoptosis in Mesenchymal Stromal Cells Induces In Vivo Recipient-Mediated Immunomodulation. *Sci Transl Med* (2017) 9:eaam7828. doi: 10.1126/scitranslmed.aa7828

56. Wang HY, Li C, Liu WH, Deng FM, Ma Y, Guo LN, et al. Autophagy Inhibition via Beclin1 Downregulation Improves the Mesenchymal Stem Cells Anti-fibrotic Potential in Experimental Liver Fibrosis. *J Cell Physiol* (2020) 235:2722–37. doi: 10.1002/jcp.29176

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, Zhou, Han, Chen, Wang, Zhuang, Lin, Zhou, Jiang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.